Tarsus Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 27, 2024
TARS$73.83+4.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations and Comprehensive Loss
(In thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Revenues: | ||
| Product sales, net | $14,729 | $— |
| License fees and collaboration revenue | 2,718 | 25,816 |
| Total revenues | 17,447 | 25,816 |
| Operating expenses: | ||
| Cost of sales | 1,593 | — |
| Cost of license fees and collaboration revenue | — | 955 |
| Research and development | 50,312 | 42,624 |
| Selling, general and administrative | 108,700 | 44,949 |
| Total operating expenses | 160,605 | 88,528 |
| Loss from operations | (143,158) | (62,712) |
| Other income (expense): | ||
| Interest income | 10,337 | 3,499 |
| Interest expense | (3,346) | (2,199) |
| Other (expense) income, net | (102) | 86 |
| Unrealized gain (loss) on equity investments | 259 | (268) |
| Change in fair value of equity warrants issued by licensee | 117 | (501) |
| Total other income, net | 7,265 | 617 |
| Loss before income taxes | (135,893) | (62,095) |
| Benefit from income taxes | — | 4 |
| Net loss | $(135,893) | $(62,091) |
| Other comprehensive loss: | ||
| Unrealized gain (loss) on marketable securities and cash equivalents | 72 | (74) |
| Comprehensive loss | $(135,821) | $(62,165) |
| Net loss per share, basic and diluted | $(4.62) | $(2.52) |
| Weighted-average shares outstanding, basic and diluted | 29,383,276 | 24,619,700 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.